

March 15, 2025

To The Corporate Relations Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Code: 540222	To The Listing Department National Stock Exchange of India Ltd., Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051 Code: LAURUSLABS
---	---

Sub: Update on proposed equity investment in KRKA Pharma Private Limited under Regulation 30(7) of SEBI (LODR) Regulations, 2015

Ref: Our intimation letter dated 06th March, 2025

Dear Sir / madam,

In continuation to our letter dated March 06, 2025 with regard to proposed acquisition of equity shares in KRKA Pharma Private Limited (“KRKA”) (a joint venture of the Company) and as per Regulation 30(7) of SEBI (LODR) Regulations, 2015, we would like to inform you that the Company has invested INR 833,000,000/- (Indian Rupees Eight Hundred and Thirty Three Million only) and acquired 83,300,000 (Eighty Three Million and Three Hundred Thousand) equity shares of KRKA at face value of INR 10/- each aggregating to an amount of INR 833,000,000/- (Indian Rupees Eight Hundred and Thirty Three Million only) by way of rights issue.

Please take the above information on record.

Yours faithfully,

For **Laurus Labs Limited**

G. Venkateswar Reddy
Company Secretary & Compliance Officer

Registered Office

Laurus Enclave, Plot Office 01, E. Bonangi Village,
Parawada Mandal, Anakapalli District - 531021, Andhra Pradesh, India.

T +91 891 682 1101, 1102, **E** info@lauruslabs.com
F +91 891 682 1103, **W** lauruslabs.com

CIN : L24239AP2005PLC047518,

Corporate Office

2nd Floor, SDE Serene Chambers, Road No. 7,
Banjara Hills, Hyderabad - 500034, Telangana, India.

T +91 40 6659 4333, 3980 4333, 2342 0500 / 501,
F +91 40 6659 4320 / 3980 4320